Behind the lead drug candidate, cannabinor, a number of CB2-selective receptor agonists are under investigation. In addition to compounds sharing the basic chemical structure of cannabinor, Pharmos scientists using advanced computational chemistry have discovered three additional chemical scaffolds from which new families of compounds have been synthesized. These families of compounds are referred to as BX, BF, and tetracyclic cannabinoids. Members of these families have demonstrated efficacy in preclinical models of pain, inflammation, immunologic dysfunction and psychiatric disease. Work is ongoing to optimize candidates from each of these series to develop increasingly potent and safe therapeutics.
Example of a BX compound suppressing tissue damage in TNBS (2,4,6-trinitrobenzenesulfonic acid)- induced bowel inflammation, a model of inflammatory disease.
Example of analgesic activity of a BF compound in a visceral pain model.
Example of three tetracyclic cannabinoids reducing the level of anxiety in an animal model.